Home > Boards > US OTC > Cannabis >

Greater Cannabis Company Inc. (GCAN)

Add GCAN Price Alert      Hide Sticky   Hide Intro
Moderator: pennypauly, Fuzzy Bunny, abe01, MR. GWINIS, KANEMAN, downandoutthanksd
Search This Board: 
Last Post: 5/21/2019 8:39:36 AM - Followers: 197 - Board type: Free - Posts Today: 9



Market Cap
Authorized Shares
Outstanding Shares
 Total Restricted Common Shares


            Aitain Zacharin, CEO                   Mark Randon, Esquire / General Counsel       David Tavor, Board of Directors                       Dr. Hock S. Tan, PHD        

____Fernando Bisker, Partner                                                                            Elisha Kalfa_______

“By improving the bioavailability of cannabinoids molecules we can deliver lower doses of actives while achieving greater therapeutic efficacy.”

- Aitan Zacharin, CEO of GCANRx


The Greater Cannabis Company, Inc.

Contact us

Corporate Headquarters
15 Walker Ave.
Suite 101
Pikesville / Baltimore, MD 21208


The Greater Cannabis Company is a holding corp whose investment strategy is centered around the cannabis sector through direct investments, acquisitions, joint ventures and e-commerce.

Patent information:
Here is patent information:

Hock Seng Tan
Siew Lian Chung

Original Assignee
Bionex Pharmaceuticals Llc
Priority date

GCAN NEWS by Date:

May 20, 2019 - FORM 10-Q Report (Quarterly Financials)

May 15, 2019 - FORM 12b-25 aka NT 10Q





Symtomax - Unipessoal Lda
Avenida D. Afonso Henriques Nº 244, 1º At
4810-431 Guimarães
Symtomax SA
1st Floor, Acacia Place, 234 Main road,
Agro Estate, Gauteng, 8032,
South Africa.

May 1, 2019 -CEO to Discuss Initial Stage of the Global Commercialization of His Company’s Proprietary Cannabinoid Delivery System, which Resemble “LISTERINE’S POCKETPACKS®


April 16, 2019 - GCAN Licenses CBD Patch Technology to
Majory Brazilian Retail Pharmacy Company


As part of the agreement, CBR Participacoes will distribute the technology to its network of 300 pharmacies and more than 1,500 point-of-sale retailers in the country, serving the Brazil’s growing demand and market for cannabis products. The agreement is effectively immediately through 2021.

“We continue to see explosive interest and growth for our technology in Brazil as the country’s cannabis market continues to expand at an exponential rate,” said Aitan Zacharin, Chief Executive Officer of Greater Cannabis Company. “Our new licensing agreement with CBR Participacoes taps into this and will represent the first of many additional agreements we are currently pursuing,” concluded Mr. Zacharin.

April 15, 2019 - SEC Update 10K

April 11, 2019 - GCAN Partners with Allume Cosmeticos
to Develope New Cosmetics Line



April 8, 2019 -GCAN Announces Expansion into CBD Cosmetic and Beauty Market

April 1, 2019 -Clinical Trials Begin

March 27, 2019 - SEC FILE NT 10K 1


March 8, 2019 - 9,000,000 Prefered Shares AMENDMENT

February 15, 2019 - SEC - 8K - Current Report
Item 1.01 Entry into a Material Definitive Agreement.
Eagle Note

On February 12, 2019 (the “Issue Date”), the Company issued a 6% Convertible Redeemable Note to Eagle Equities, LLC (“Eagle”), having a principal amount of $1,200,000 of which $96,000 constituted an original issue discount (the “Eagle Note”). In connection with the Eagle Note, the Company and Eagle entered into a Securities Purchase Agreement. The Eagle Note will mature on the earlier of twelve (12) months from the Issue Date

February 14, 2019 - FORM 8-A SEC Filed

February 13, 2019 - OTCQB Certification Filed

February 5, 2019 - OTCQB Certification filed

January 28, 2019 - Annual Report (Florida) Filed

January 27 - Israel Gives Green Light to Medical Cannabis Exports

January 25, 2018 - OTCQB Certification
"Number of shares in the Public Float: 15,529,536 as of January 25, 2019"

January 23, 2019 - OTC MARKETS Registering to UPLIST OTCQB

January 3, 2019 - FORM 3 Filed OTCMARKETS
Benificial Ownership Registration


January 7,2019 - World Wide Distribition Deal with Ican


Expanded Distribution to Accelerate Commercialization of Eluting Patch Platform into the Global Marketplace

Baltimore, MD, Jan. 07, 2019 (GLOBE NEWSWIRE) -- The Greater Cannabis Company, Inc. (OTC: GCAN) (“the Company”), a biopharmaceutical company focused on development and commercialization of innovative delivery systems for the Cannabis market is pleased to announce that it has entered into a letter of intent with iCAN Cannabis to expand distribution of its eluting patch platform into key global markets. The eluting patch platform is an innovative delivery system, which uses a patented mucoadhesive and multilayered orally dissolving thin film to deliver a precise dose of cannabinoids into the body through the buccal mucosa. Clinical studies funded in part by the National Institutes of Health (NIH) have shown the delivery system’s capability in achieving higher bioavailability and desired results in the body using lower, and controlled, dosing when compared to other routes of administration.

The agreement with iCAN will include commercial ready formulations to meet medical and recreational market demands. Distribution and marketing rights for iCAN will include Israel, Australia, South Africa, Netherlands, South Africa, Mexico, Colombia, Panama, Germany, Austria, Switzerland, Malta, Macedonia, and Portuguese territories.

iCAN is a global company focused on the cannabis ecosystem. iCAN operates a global platform for distribution of cannabis products through its iCAN Serve unit with an expansive footprint. iCAN also holds a portfolio of companies including CannRx, an extraction and formulation business and CMTREX, a commodities trading platform for the cannabis industry, CannaTech, the leading producers of global cannabis conferences focused on research, science, and innovation, and endoCRO, a contract research organization spearheading therapeutic focused studies.

Industry leader and CEO of iCAN, Saul Kaye, said of the transaction, “I am very excited about the prospect of offering GCAN’s products through our many distribution channels.” “I have seen many groundbreaking innovations come through our CannaTech conferences, and the eluting patch technology was a platform I was particularly impressed with. I believe this technology can redefine how consumers think about cannabis. From the lower dosage form, to the controlled and slow release mechanisms, and the ability to use it anywhere, I believe the product will resonate really well with consumers and generate rapid traction in the markets we intend to bring it to.”

Aitan Zacharin, CEO of Greater Cannabis said, “I am pleased to announce our partnership with iCAN. Saul is an industry leader who is at the forefront of everything tech in cannabis. His desire to partner with us is a testament to the strength of our technology, and its capabilities. We are excited to establish this important partnership in the medical and adult-use cannabis industry. We are focused on transactions that will accelerate commercialization of our products, and the iCAN deal does that globally.” “iCAN shares our enthusiasm for seeing healthier, standardized, pharmaceutical-grade, and more cost-effective cannabis products introduced into the market. We look forward to working with iCan to bring our cutting-edge technology to consumers worldwide.”

About iCAN: Israel-Cannabis

iCAN: Israel-Cannabis is a leading Israeli developer of cannabis-based formulations, clinical trials and cannabis testing. iCAN is committed to accelerate Israel's Canna-Technology industry, capitalizing on Israeli innovation and a leading cannabis regulatory environment to bring premier products to market. iCAN is powered by CannaTech, the premier international cannabis summit held annually in Tel Aviv, and around the world including London, Sydney, Hong Kong and now Panama in 2019.

November 19, 2018 - FORM 10 Q

November 15, 2018 - 8K/8 Amendment No.1

November 14, 2018 -NT 10Q -SEC Notification of Inability to timely fiel form 10-Q or 10-QSB


November 2, 2018 - News Release

Innovative Cannabis Delivery Technologies on the Rise:
The Greater Cannabis Company, Inc. (OTC: GCAN), Aphria, Tilray, Aurora and Canopy Growth


October 31, 2018 - News Release

The Greater Cannabis Company to Update Shareholders on Corporate Strategy and
Developments of Eluting Patch Platform (EPP) for Cannabinoid Use


October 11, 2018 - The Greater Cannabis Company Files Additional Patent
to Further Protect Proprietary Cannabinoid Delivery System


October 11, 2018 13:15 ET | Source: The Greater Cannabis Company, Inc.

Baltimore, MD, Oct. 11, 2018 (GLOBE NEWSWIRE) -- The Greater Cannabis Company, Inc. (OTC: GCAN) (“the Company”), a biotechnology company focused on development and manufacturing of innovative delivery systems for the Cannabis market, today announced that it has filed an additional patent to further protect its proprietary Eluting Transmucosal Patch (ETP) platform. The United States Patent and Trademark Office has accepted the filing entitled, Oral Dissolving Film for Rapid and Sustained Release and Delivery of Cannabinoids, and as of September 27, 2018 has issued the Company a priority application number of US 62/737,153. The Company’s ETP technology has a unique mode of action, which allows for both a rapid onset of delivery, as well as a controlled slow and sustained release of drug actives over several hours. The eluting patch technology allows the proprietary thin film to firmly attach to the oral mucosa while being non-irritating and unnoticeably thin. Upon administration in the oral cavity, the eluting patch can release different cannabinoids at different dosages and rates depending on the desired effect.

“We are rapidly building our intellectual property portfolio surrounding our innovative and proprietary technology. We believe we have several points of difference with our ETP platform, which are novel and will offer greater economic and desired effects for the industry”, said Aitan Zacharin CEO of Greater Cannabis. “We can now facilitate the controlled release of active agents quicker and with a greater bioavailability than more conventional methods of cannabinoid administration. With this patent filing we are further fortifying our competitive advantage.”

The global market opportunity for Cannabis is rapidly growing,and projected to reach over $30 billion according to recent studies. The need for safer and more effective routes of administration remains unmet. The Company believes its technology is well positioned to help solve this problem and intends to seek commercialization partners for the eluting patch technology in the United States and globally. The Greater Cannabis Company’s technology is protected by multiple global issued patents under its license with Pharmedica, an Israeli-based biopharmaceutical company. The Company intends to submit additional patent applications, which are currently in process.  More information on the Greater Cannabis Company and its technology can be found on the Company’s new website, www.gcanrx.com.

October 8, 2018 - New Corporate Website was launched

October 4, 2018 - The Company Appoints Dr. Hock Tan as Chairman of Scientific Advisory Board


The Greater Cannabis Company, Inc. (OTCPK: GCAN) (“the Company”) a biotechnology company focused on innovative delivery systems for the Cannabis market, is pleased to announce that Dr. Hock Tan, Ph.D. will serve as Chairman of the Company’s Scientific Advisory Board. As chairman, Dr. Tan will help to advance ongoing research and development, formulation, manufacturing, as well as contributing to the Company’s intellectual property strategy. Additionally, Dr. Tan will work with the Company to spearhead studies, which will further substantiate the Company’s innovative eluting patch technology as an effective Cannabinoid delivery system. Dr. Tan will also be involved in evaluating other ground-breaking technologies, which align with the Company’s mission to bring forward scientifically driven innovations to the Cannabis market.

Hock S. Tan, PhD, Founder/CEO   Dr. Tan has 20 years of experience in pharmaceutical product development, with expertise in drug delivery systems. His career spans over a broad range of areas including R&D, business development, process engineering, project management, and product commercialization.

September 26, 2018 - 8K filed with Sec

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) Appointment of Directors

Effective September 24, 2018, the Company’s board of directors appointed David Tavor as a director of the Company. Mr. Tavor does not have any family relationships with any other executive officers or directors of the Company, or persons nominated or chosen by the Company to become directors or executive officers. There is no arrangement or understanding pursuant to which Mr. Tavor was appointed as a member of the Board. Furthermore, the Company is not aware of any transaction requiring disclosure under Item 404(a) of Regulation S-K, except for the Exchange Transaction. It is contemplated that Mr.Tavor may serve on certain committees of the Board, but no such committee appointments have been made at this time.

September 24, 2018 - News Release

The Greater Cannabis Company Announces Appointment of David Tavor to its Board of Directors

The Greater Cannabis Company Inc.





PharMedica is a privately held company founded in 2008, specializing in the Biotech and Medical Device industries.The company developed an “Eluting Bandage Platform” - a multifunctional, multilayer, intra-oral drug delivery platform.This mucoadhesive film is applied on the internal mouthtissue. Firmly attached yet totally non-irritant, it disintegrates and dissolves as the treatment progresses.The Eluting Bandage Platform is aimed at two major markets: Oral-Care, and Trans-membrane Drug Delivery.

THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is made and entered into as of June 21, 2018 (the “Effective Date”), by and between Pharmedica Ltd. an Israeli company (“Pharmedica”), and Green C Corporation a company incorporated under the laws of Canada with its principal place of business at 1 Whitehorse Road, Unit 16, Toronto, Ontario M3J 3G8 (“Licensee”). Pharmedica and Licensee each may be referred to herein individually as a “Party,” or collectively as the “Parties”.

WHEREAS, Pharmedica has developed and is the sole owner of or the exclusive licensee of the Licensed Patent and related Know-How; and

WHEREAS, Pharmedica is, as at the Effective Date, and intends to continue to be, involved with a third party company (“Third Party Company”) in the development and eventual commercialization of a product exploiting the Pharmedica Patent(s) and related Know-How for applications in the oral care field; and

WHEREAS, Pharmedica wishes to grant to Licensee and Licensee is willing to receive from Pharmedica an exclusive license under the Pharmedica IP to develop, market, use, sell, offer for sale, import, export, manufacture, commercialize and distribute the Licensed Product all in accordance with the terms and conditions of this Agreement; and

WHEREAS, each Party hereto has the ability, expertise and experience to perform its obligations hereunder.


1. Preamble, Appendices and Interpretation
1.1 The Preamble and Appendices hereto form an integral part of this Agreement
1.2 In this Agreement the following terms shall bear the meanings assigned to them below, unless specifically stated otherwise
  1.2.1 “Affiliate” shall mean, with respect to any party hereto, any person, organization or entity directly or indirectly controlling, controlled by or under common control with, such party. For purposes of this definition only, “control” of another person, organization or entity shall mean the ability, directly or indirectly, to direct the activities of the relevant entity, and shall include, without limitation (i) ownership or direct control of fifty percent (50%) or more of the outstanding voting stock or other ownership interest of the other organization or entity, or (ii) possession of, or the power to elect or appoint fifty percent (50%) or more of the members of the governing body of the organization or other entity.
  1.2.2 Derivative Work” shall mean a work that is based upon one or more preexisting works, such as a revision, modification, translation, abridgment, condensation, expansion, or any other form in which such preexisting works may be recast, transformed or adapted and that if prepared without the authorization of the owner of the preexisting work would constitute an infringement of the proprietary rights of the owner therein
  1.2.3 First Commercial Sale” shall mean, with respect to any Licensed Product in any country, the first commercial sale to a third party by Licensee or its Affiliates or Sublicensees, in exchange for cash or some equivalent to which value can be assigned.
  1.2.4 Intellectual Property Rights” shall mean all intangible legal rights, titles and interests, evidenced by or embodied in: (i) all inventions, patents, provisionals, patent applications (whether pending or not), and patent disclosures together with all reissuances, continuations, continuations in part, revisions, extensions, and reexaminations thereof; (ii) all trademarks, service marks, copyrights, designs, trade styles, logos, trade dress, and corporate names, including all goodwill associated therewith; (iii) any work of authorship, regardless of copyrightability, all compilations, all copyrights (including the droit morale); (iv) all trade secrets, and proprietary processes, licenses; and (v) all Derivative Works of the above and all other proprietary rights and any other intellectual property rights of any kind and nature however designated and however recognized in any country or jurisdiction worldwide.

Licensed Product” shall mean Pharmedica’s patch described in Annex A hereto in combination with Cannabidiol (CBD) for medical or recreational cannabis, where latter permitted for the transmucosal delivery of medicinal or recreational cannabis, where latter permitted (other than in the field of oral care) or any other product exploiting the Licensee Cannabis IP for the transmucosal delivery of medicinal or recreational cannabis, where latter permitted.

  1.2.6 Marketing Approval” shall mean, with respect to any country, the obtaining of all necessary regulatory approvals (excluding the obtainment of pricing and reimbursement) required in order to commercially sell and market the Licensed Product in such country.
  1.2.7 Pharmedica IP” shall mean the Pharmedica Patents and all Intellectual Property Rights embodied therein and/or related thereto and the Pharmedica Know-How.
  1.2.8 Pharmedica Know-How” shall mean the formulation information that the Company will deliver to Elisha Kalfa.
  1.2.9 Pharmedica Patents” shall mean those patents and patent applications listed in Annex B, as well as patents issuing therefrom, and any substitutions, divisions, continuations, continuations-in-part (but only to the extent that they cover the same invention claimed in the foregoing), reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates and the like, and any provisional applications, of any such patents or patent applications.
  1.2.10 Net Sales” shall mean, with respect to each Licensed Product, the total amounts invoiced by or on behalf of Licensee, its Affiliates and their Sublicensees (in each case, the “Invoicing Entity”) on sales of Licensed Products to third parties in bona fide arms length transactions, less deductions for the following items to the extent they are actually allowed and incurred and specifically identifiable as directly related to such License Products in the invoiced amounts: (a) cash discounts; (b) returns of goods as a result of recalls and returns of damaged goods; (c) rebates relating to government mandated programs; and (d) customs, duties, sales, withholding (to the extent not refundable) and similar taxes to the extent such charges were added to the sales price of the Licensed Products.

Net Sales shall not include sales by Licensee or one of its Affiliates to other of Licensee’s Affiliates, Sublicensees or contractors for resale, except if such Affiliate, Sublicensee or contractor is an end user of the Licensed Products; rather, in each such instance, Net Sales shall include the amounts invoiced by such Affiliate, Sublicensees or contractors to independent unrelated third parties, in bona fide arm’s length transactions. For purposes of this Agreement, “sale” shall not include reasonable transfers of a Licensed Product at no charge for regulatory or clinical trials purposes; provided that the quantity of Licensed Products actually utilized for purposes of such trials shall not exceed five percent (5%) of the volume of annual Licensed Product sales during any calendar year.

In calculating Net Sales, all amounts shall be expressed in US Dollars and any amount received in a currency other than US Dollars shall be converted in accordance with section 4.6.

  1.2.11 Sublicense” shall mean any right granted, license conferred, or agreement entered into, by Licensee or its Affiliates to or with any other person or entity, permitting any use of the Pharmedica IP or the Licensed Products, whether or not such grant of rights license or agreements entered into is described as sublicense or as an agreement with respect to the development and/or manufacture and/or marketing and/or distribution and/or sale.
  1.2.12 Sublicense Receipts” shall mean all consideration, whether monetary or otherwise, received by Licensee and/or its Affiliates from a Sublicensee in consideration for the grant of a sublicense hereunder, and/or pursuant thereto, or in consideration for the grant of an option for a Sublicense, except for amounts received by Licensee and/or its Affiliates from a Sublicensee which constitute royalties based on Net Sales of Licensed Products. Any Sublicense Receipts received by Licensee in the form of non-cash compensation shall be valued at fair market value, and Sublicense Fees shall be paid by Licensee to Pharmedica in respect of such Sublicense Receipts either in cash or in specie as received by Licensee (at Pharmedica’s sole discretion).
1.3 In this Agreement, words importing the singular shall include the plural and vice-versa and words importing any gender shall include all other genders and references to persons shall include partnerships, corporations and unincorporated associations.
1.4 In the event of any discrepancy between the terms of this Agreement and any of the Annexes or Appendices hereto, the terms of this Agreement shall prevail.
2. LICENse


2.1 During the term of this Agreement and subject to the terms and conditions of this Agreement, Pharmedica hereby grants to Licensee an exclusive license to exploit the Pharmedica IP solely as necessary to develop, manufacture, market, use, sell, offer for sale, import, export, commercialize and distribute the Licensed Products (the “License”)


2.2 The License shall be sub-licensable, subject to any reasonable objection by Pharmedica to a specific sublicensee. Any such sublicense shall not release Licensee from any liability for performance under this Agreement and Licensee shall be responsible for assuring the compliance of its sublicensees with the relevant terms and conditions of this Agreement. A copy of any Sublicense agreement entered into by Licensee shall be submitted to Pharmedica following execution.

Licensee may only perform and/or subcontract development activities to third parties approved in advance and in writing by Pharmedica.

2.3 Pharmedica shall provide to Licensee Pharmedica’s available specifications, processes, materials, and any other documentation related to the Pharmedica IP as is reasonably necessary or useful to enable Licensee to utilize the License granted to Licensee under this Agreement. In addition, Pharmedica will make available personnel as reasonably requested by Licensee, to provide such individual training to Licensee’s technical personnel as is necessary to enable Licensee to utilize the License, at such reasonable times and places as Licensee may request from time to time. All Pharmedica’s costs incurred or expended in performing the foregoing shall be reimbursed to Pharmedica by Licensee.
2.4 Subject only to the License, all right, title and interest in and to the Licensed Product and the Pharmedica IP and all right, title and interest in and to any drawings, plans, diagrams, specifications, other documents, models, or any other physical matter in any way containing, representing or embodying any of the aforegoing vest and shall vest in Pharmedica. In addition, it is clarified that nothing contained in this Agreement shall prevent Pharmedica from freely using and exploiting the Pharmedica IP and/or Intellectual Property Rights relating to the Licensed Product, including without limitation those developed or first reduced to practice by or on behalf of Licensee, its Affiliates or Sublicensees, in respect of products based on or exploiting the Pharmedica IP for use in oral care applications or any other applications whatsoever (other than the transmucosal delivery of medicinal or recreational cannabis, where latter permitted).
2.5 Pharmedica makes no warranties whatsoever as to any results to be achieved in consequence of the carrying out of any development efforts or activities; or that the Pharmedica IP or any part thereof is or will be valid or will afford proper protection or that the Pharmedica IP will be commercially exploitable or of any other value.

Licensee acknowledges that it is aware that Pharmedica is in the process of effecting a commercial transaction with the Third Party Company with regard to Pharmedica’s patch described in Annex A hereto and Pharmedica IP, as well as certain related technology, for oral health applications. Licensee undertakes to assist Pharmedica as required to promote such transaction, and not to take any action the consequence of which might be harmful to the chances of such transaction being executed and/or implemented or might reasonably be expected to delay such transaction. Without derogating from the generality of the foregoing, Licensee undertakes to assign or to license all its right, title and interest to the Licensee Cannabis IP (as defined below) to Pharmedica or such Third Party Company, as may be required by Pharmedica, for reasonable consideration

3.1 Licensee shall, at its own expense, exert continuing best efforts to develop and commercialize the Licensed Product.
3.2 Furthermore, Licensee shall be required to meet the development, regulatory and sales milestones set forth in Annex C attached hereto by the respective dates set forth therein. For avoidance of doubt, failure to meet any of the aforesaid milestones shall entitle Pharmedica to terminate the License.
3.3 Licensee shall perform its obligations hereunder in accordance with all applicable laws and regulations, and shall procure the receipt of all approvals and consents necessary for the performance of its obligations under the terms hereof.
3.4 At the end of each calendar quarter, Licensee shall provide Pharmedica with a sales report and once yearly Licensee shall provide Pharmedica with written progress reports of its activities, which reports shall include detailed descriptions of the progress and results, if any, of: (i) the tests and trials conducted; (ii) manufacturing of the Licensed Product, (iii) the status of sublicensing and sales as well as (iv) details of new clinical and regulatory data developed pursuant hereto, and any adverse events.
4. Financial Provisions
4.1 License Fee. Licensee shall pay Pharmedica a license fee of $100,000, payable as follows: (A) $50,000 (fifty thousand US dollars) shall be paid within three (3) days of the Effective Date and (B) $50,000 (fifty thousand US dollars) shall be paid within three (3) days of Licensee’s first receipt of an acceptable quote from Dr. Hock Tan of Bionex Pharmaceuticals, Inc (“Bionex”), related to the Licensed Product or the development thereof. .
4.2 Royalties. Licensee shall pay Pharmedica annual royalties at a rate of five percent (5%) of the Net Sales of the Licensed Product (“Royalties”).
4.3 Minimum Royalties. As of the first anniversary of the Effective Date, in the event that the Royalties payable in respect of any calendar year are less than $50,000 (the “Minimum Annual Royalty”), Licensee shall pay, in addition to the Royalties, an amount equal to the difference between such amount and the Minimum Annual Royalty within ninety (90) days of the end of the applicable calendar year. In the event that this Agreement is terminated by either party for any reason before the end of any calendar year, the Minimum Annual Royalty due for such year, if any, shall be prorated based on the proportion of the year elapsed prior to the effective date of such termination.
4.4 Sublicense Fees. In addition, Licensee shall pay Pharmedica five percent (5%) of Sublicense Receipts in addition to seven and one half percent (7.5%) of the proceeds of any sale of the Licensee (“Sublicense Fees”)
4.5 Reports. As of the First Commercial Sale, and for the duration of the Agreement, Licensee shall submit to Pharmedica, no later than forty-five days (45) after the end of each quarter, quarterly reports detailing the amounts due to Pharmedica pursuant hereto, and detailing the Net Sales made by Licensee and its Affiliates and Sublicensees during such period. Such reports shall also detail the quantities of Licensed Products sold, applicable offsets (on a gross basis) and withholding taxes.
4.6 Payment. Royalties payable to Pharmedica shall be paid on a quarterly basis, no later than thirty (30) days after the end of each calendar quarter, and Sublicense Fees shall be paid within seven (7) days of receipt of the applicable Sublicense Receipts; all by wire transfer of immediately available funds to an account designated by Pharmedica in writing. With respect to sales of Products in foreign currency on which any Royalties are payable hereunder, conversions to U.S. dollars shall be made based on interbank (official) rates as reported on www.oanda.com as of the first business day of the month in which the payment is to be made.
4.7 Audit. Licensee shall maintain, and shall cause its Affiliates and Sublicensees to maintain, complete and accurate records of amounts payable to Pharmedica in relation to Licensed Products, which records shall contain information to reasonably permit Pharmedica to confirm the accuracy of any reports or payments to Pharmedica under this Agreement. All such records shall be retained for at least five (5) years after the conclusion of the applicable calendar year, during which time Pharmedica shall have the right, at its expense, to cause an independent, certified public accountant to inspect such records during normal business hours for the sole purpose of verifying any reports and payments delivered under this Agreement. The parties shall reconcile any underpayment or overpayment within thirty (30) days after such accountant delivers the results of the audit. In the event that any audit reveals an underpayment in excess of five percent (5%), then Licensee shall bear the full cost of such audit.
6.1 Existing Technology. Other than as explicitly set forth in this Agreement, nothing in this Agreement shall be construed as granting either Party any right or license to the other Party’s existing Intellectual Property Rights as of the Effective Date or in Derivative Works thereof.
6.2 Pharmedica IP. All Pharmedica IP will be owned exclusively by Pharmedica and shall be subject to the License granted hereunder.
6.3 New IP. All Intellectual Property Rights embodied in and/or related to the Licensed Product(s), all marketing materials and all related data and know-how, and all Intellectual Property Rights generated, made, conceived, developed, or reduced to practice, after the Effective Date hereof and related to the Licensed Product, including any improvements or modifications to the Pharmedica IP, shall be exclusively owned by Pharmedica and deemed included in the definition of Pharmedica IP (even if same were developed or reduced to practice by or on behalf of Licensee).

Notwithstanding the foregoing, any such newly developed IP developed or reduced to practice solely by or on behalf of Licensee specifically for use in the delivery of medicinal or recreational cannabis, where latter permitted (“Licensee Cannabis IP”) shall be owned by the Licensee, and Pharmedica shall have a perpetual, non-exclusive royalty-free license to exploit same at its discretion.

6.4 Assistance Regarding IP. Each Party hereto undertakes to sign, execute and deliver all documents and papers that may be required, and perform such other acts as may be reasonably required in the circumstances, in order to ensure the allocation of the intellectual property rights between the Parties in accordance with the terms of this Section.
7.1 Patent Filing and Prosecution. Pharmedica shall be responsible for the filing, prosecution and maintenance of all patents and patent applications included in the Pharmedica IP and/or related to the Licensed Product.
7.2 Patent Enforcement. Each of Pharmedica and Licensee shall promptly notify the other if it knows or has reason to believe that any of the rights to the Pharmedica IP and/or related to the Licensed Product are being infringed or misappropriated by a third party or that such infringement or misappropriation is threatened. The parties shall consult with each other as promptly as reasonably practicable to review actions to be taken in connection with such alleged infringement or misappropriation.

Only Pharmedica shall be entitled to take action to alleviate any such alleged or threatened infringement or misappropriation at its sole discretion.

In case of such action, Licensee will fully cooperate with Pharmedica with respect to the investigation and prosecution of such alleged infringement or misappropriation including the eventual joining of Licensee as a party to such action, if so required by the law of the particular forum where enforcement is being sought. Any recovery obtained as a result of such enforcement action shall be applied first to the documented legal fees and other costs actually incurred in connection with the action, and the remainder of such recoveries shall be retained by Pharmedica.

7.3 Defense against Claims of Infringement. In the event that during the term of this Agreement a suit or action is brought against either Pharmedica or Licensee, or both of them, by a third party alleging that the commercialization of the Licensed Products infringes upon any Intellectual Property Rights of such third party the Party being so sued shall immediately give the other Party notice of same.

Licensee shall have the first right, but not the obligation, to defend against such action, on behalf of both Parties, within the appropriate time, and any expenses or costs incurred by Licensee in connection with such action(s), and any costs or amounts awarded to the counterparties in such action(s), shall be fully borne by Pharmedica and any recovery in such action shall be applied first to the documented legal fees and other costs actually incurred by Pharmedica in connection with the action, and the remainder of such recoveries shall be retained by Pharmedica.

In the event that Licensee does not exercise its right to so defend as set forth above, then Pharmedica shall be entitled to defend against such claim at its own cost and expense and any recovery in such action shall be retained by Pharmedica in full. In addition, and without derogating from Pharmedica’s other rights and remedies, in such event that Pharmedica defends against such claim, Pharmedica shall have the right to terminate the License in accordance with the provisions of Section 12.3(i) [termination for breach].

7.4 Under no circumstances shall Licensee challenge or attempt to invalidate, directly or indirectly, the validity of any of the Pharmedica Patents during the term of this Agreement or at any time thereafter.
7.5 In no event shall either Party when defending the other party, enter into any settlement, consent order, consent judgment or any voluntary disposition of such action that would adversely affect the rights of the other without the prior written consent of such other Party, which consent shall not be unreasonably withheld.
8.1 Each Party hereby warrants that (i) it has the full power and authority to enter into this Agreement and to convey the rights herein conveyed; (ii) entering this Agreement and performance hereof shall not constitute a breach of any agreement, contract, understanding and/or obligation, or any third party rights including its documents of incorporation that it is currently bound by; (iii) it shall perform its obligations hereunder diligently, expeditiously and to the best of its abilities; and (iv) it has the financial capacity, as well as the necessary experience and expertise, to carry out all its obligations hereunder, and that in carrying out its undertakings and responsibilities pursuant to this Agreement, it shall obtain or procure all necessary approvals and consents and shall comply with all applicable laws and regulations, licenses, permits, and approvals.
8.2 Pharmedica further warrants that to its knowledge, no third party has provided Pharmedica with written notice contesting the ownership or validity of the Pharmedica IP.
9.1 Licensee shall defend, indemnify and hold Pharmedica, its Affiliates, and the officers, directors and employees and consultants of each of them, harmless from and against any losses, costs, damages, fees or expenses (including reasonable attorneys fees) suffered by them relating to (i) any breach by Licensee of its obligations hereunder or (ii) any activities conducted by or for Licensee under this Agreement, or (iii) any product liability claims related to the Licensed Product or the marketing or sale thereof.
10.1 Other than as expressly set forth herein, Licensee and Pharmedica undertake to treat and to maintain and to ensure that their Representatives (as defined below) shall treat and maintain, in strict confidence and secrecy any information disclosed by the other Party prior to the Effective Date or thereafter under this Agreement, whether disclosed in oral or visual form or in writing and shall keep in confidence the existence and contents of this Agreement (the “Confidential Information”) and shall not disclose, publish, or disseminate in any manner, any Confidential Information to a third party other than those of its Representatives with a need to know same for the purpose of performing its obligations under this Agreement. In addition, each Party shall undertake to treat and maintain (and to ensure that its Representatives treat and maintain) in strict confidence and secrecy and to prevent any unauthorized use, disclosure, publication, or dissemination of the Confidential Information, except for the purpose of complying with this Agreement. Each Party agrees to be responsible for any use or disclosure of Confidential Information of any of its said Representatives. It is clarified that the Pharmedica IP and any IP subject to the provisions of Section 6.3 above shall constitute Pharmedica’s Confidential Information.
10.2 Each Party shall: (i) safeguard and keep secret all Confidential Information, and will not directly or indirectly disclose to any third party the Confidential Information without written permission of the other; and (ii) in performing its duties and obligations hereunder, use at least the same degree of care as it does with respect to its own confidential information of like importance but, in any event, at least reasonable care
10.3 The undertakings and obligations under this Section 10 shall not apply to any part of the Confidential Information which:
  (a) was known to the recipient of the Confidential Information (“Recipient”) prior to disclosure by the disclosing Party (“Discloser”);
  (b) was generally available to the public prior to disclosure to the Recipient;
  (c) is disclosed to Recipient by a third party who is not bound by any confidentiality obligation, having a legal right to make such disclosure;
  (d) has become through no act or failure to act on the part of the Recipient public information or generally available to the public; or
10.4 Licensee and Pharmedica acknowledge that the respective Confidential Information is of special and unique significance to each of them and that any unauthorized disclosure or use of the Confidential Information could cause irreparable harm and significant injury to the Discloser that may be difficult to ascertain. Accordingly, any breach of this Agreement may entitle the aggrieved Party in addition to any other right or remedy that it may have available to it by law or in equity, to remedies of injunction, performance and other relief, including recourse in a court of law.
10.5 The provisions relating to confidentiality in this Section 10 shall remain in effect during the term of this Agreement and for a period of ten (10) years after its termination.
10.6 Representatives” shall mean employees, officers, agents, subcontractors, consultants, and/or any other person or entity acting on either Party’s behalf, individually or collectively and which shall be exposed to Confidential Information.

Neither Party shall issue any press release, make any public statement or advertise any information pertaining to this Agreement, or to the collaboration hereunder, without the prior written approval of the other, except as required by applicable law. Without derogating from the foregoing, disclosure required under applicable law and regulations shall not be subject to the written consent of the other Party, however the disclosing party shall give the other sufficient notice, as far as practicable under law, of such required disclosure as to enable the non-disclosing Party time to object to such disclosure.

12.1 This Agreement is subject to the approval of the Board and Shareholders of the Company, and in the event such approval is not obtained within 30 days as of the signing hereof, this Agreement shall be null and void ab initio and any payments made hereunder shall be returned.
12.2 This Agreement shall be effective from the date of signature of the last signing party to the Agreement (the “Effective Date”) and shall continue in full force and effect subject to Section 12.1 above, unless earlier terminated, in accordance with this Section 12.
12.3 Without derogating from any other remedies that any Party hereto may have under the terms of this Agreement or at law, each Party hereto shall have the right to terminate this Agreement forthwith upon the occurrence of any of the following:
  (i) the commission of a material breach by the other Party hereto of its obligations hereunder, and such other Party’s failure to remedy such breach to the reasonable satisfaction of the other Party within thirty (30) days after being requested in writing to do so; or
  (ii) the other party’s liquidation, whether voluntarily or otherwise, or if it makes an assignment for the benefit of creditors.
12.4 Upon termination of this Agreement by Pharmedica pursuant to the provisions of Section 12.3 (ii) above [Licensee’s liquidation], all right, title and interest in and to the Licensee Cannabis IP shall automatically be assigned, and is hereby assigned, to Pharmedica for no further consideration.
12.5 The termination of this Agreement for any reason shall not relieve either Party hereto of any obligations which shall have accrued prior to such termination.
12.6 The following provisions of this Agreement shall survive the termination or expiration hereof: 1, 4.7, 6, 7.1, 7.2, 7.4, 7.5, 9, 10, 11, 12.4, 12.5, 12.6, 14 and 15.

Each Party hereto shall maintain, for the term of this Agreement and thereafter, insurance sufficient to cover its obligations under this Agreement and under law.

14. Jurisdiction

This Agreement shall be governed by and construed in accordance with the laws of the State of Israel. The Parties hereto hereby consent to the exclusive jurisdiction of the appropriate court of Tel Aviv-Jaffa with respect to any matter related to this Agreement.

15.1 The headings in this Agreement are intended solely for convenience or reference and shall be given no effect in the interpretation of this Agreement.
15.2 This Agreement (including the Annexes attached hereto) constitutes the entire agreement between the Parties with respect to its subject matter and supersede all prior agreements, arrangements, dealings or writings between the Parties.
15.3 This Agreement may be executed in any number of counterparts (including counterparts transmitted by fax), each of which shall be deemed to be an original, but all of which taken together shall be deemed to constitute one and the same instrument.
15.4 Neither Party hereto may assign its rights and/or obligations hereunder in whole or in part, without the prior written consent of the other Party hereto, provided that either Party shall be entitled, at any time, to assign this Agreement to an Affiliate of such Party or to a party which acquires all or substantially all of that party’s business related to this Agreement, whether by merger, sale of assets or otherwise, provided that the assigning Party shall guarantee performance of any and all financial liabilities hereunder by such transferee.
15.5 No waiver of a breach or default hereunder shall be considered valid unless in writing and signed by the Party giving such waiver and no such waiver shall be deemed a waiver of any subsequent breach or default of the same or similar nature. No failure by any party hereto to take any action against any breach of this Agreement or default by another party hereto shall constitute a waiver of the former party’s rights to enforce any provision of this Agreement or to take action against such breach or default or any subsequent breach or default by such other party.
15.6 Should any part or provision of this Agreement be held unenforceable or in conflict with the applicable laws or regulations of any applicable jurisdiction, the invalid or unenforceable part or provision shall, provided that it does not go to the essence of this Agreement, be replaced with a revision which accomplishes, to the extent possible, the original commercial purpose of such part or provision in a valid and enforceable manner, and the balance of this Agreement shall remain in full force and effect and binding upon the Parties hereto.
15.7 This Agreement shall make neither Licensee nor Pharmedica the agent or legal representative of the other. Each Party shall be an independent contractor, not an employee or partner of the other Party, and the manner in which each Party renders its services under this Agreement shall be within its sole discretion. Neither Licensee nor Pharmedica is granted any right or authority to assume or to create any obligation or responsibility, express or implied, on behalf of or in the name of the other, with regard to any manner or thing whatsoever, unless otherwise specifically agreed upon in writing.
15.8 Each Party agrees to execute, acknowledge and deliver such further documents and instruments and do any other acts, from time to time, as may be reasonably necessary, to effectuate the purposes of this Agreement.
15.9 None of the provisions of this Agreement shall be enforceable by any person who is not a party to this Agreement.
15.10 The remedies afforded to any of the parties hereto, whether hereunder, or under applicable law or otherwise, shall be cumulative in nature and not alternative.
15.11 Force Majeure. Neither party shall be responsible to the other for failure or delay in performing any of its obligations under this Agreement or for other non-performance hereof but only to the extent that such delay or non-performance is occasioned by a cause beyond the reasonable control and without fault or negligence of such party, including, but not limited to earthquake, fire, flood, explosion, discontinuity in the supply of power, court order or governmental interference, strikes, act of God, strike or other labor trouble, act of war or terrorism and provided that such party will inform the other party as soon as is reasonably practicable and that it will entirely perform its obligations immediately after the relevant cause has ceased its effect.
15.12 Notice, declaration or other communication required or authorized to be given by any Party under this Agreement to any other Party shall be in writing and shall be personally delivered, sent by facsimile transmission (with a copy by ordinary mail in either case) or dispatched by courier addressed to the other Party at the address stated below or such other address as shall be specified by the Parties hereto by notice in accordance with the provisions of this Section. Any notice shall operate and be deemed to have been served, if personally confirmed as delivered, successfully sent by fax or by delivered by courier on the next following business day. Licensee’s and Pharmedica’s addresses for the purposes of this Agreement shall be as follows:

Green C Corporation: 1 Whitehorse Road, Unit 16, Toronto, Ontario M3J 3G8

Tel: 416-661-0728; Attn: Elisha Kalfa; E-mail: elisha@focusglobalsupply.com

Pharmedica: 9 Andre Saharov, Matam, Building #25, Haifa 508409, Tel: +(972) 04 8342155; Fax: +(972) 04 8341233 Attn: Dr. Yoram Rubin, CEO E-mail yrubin@pharmedica.co.il

with a copy (which shall not constitute notice) to: Tulchinsky Stern Marciano Cohen Levitski & Co., 4 Berkowitz Street, Museum Tower, 12th Floor, Tel-Aviv 6423806, Fax: +972-3-607-5050, Attn: Adv. Alon Tabak Aviram; Email: alont@tslaw.co.il.


IN WITNESS WHEREOF, each of the Parties has executed this Agreement and the Annexes hereto. 

Green C Corporation   PHARMEDICA LTD.
signature:   signature:
name:   name:
designation:   designation:
date:   date:

Annex A – Description of Patch

A “Eluting Transmucosal Patch Platform (ETP)” for non-invasive drug delivery.


Annex B – Patent(s)/Patent Application(s)

1. WO 2012/104834 A1

New oral dissolving films for insulin administration, for treating diabetes.

filed on December 2011. National Phase at Israel and the USA.

2. WO 2010/135053 A2

Dual and single layer dosage forms.

Issued USA patent on April 28, 2015.

3. PCT/IL 2017/050845

Adhesive Oral dissolved Films in Managing Oral Care.

PCT on 31 July 2017.


Annex C – Diligence Milestones

Licensee is required to meet the following development/regulatory/commercialization milestones in order to retain the license:

  ? Successful completion of the development of product samples by the end of year 1, provided there are no delays which are under the control of Licensee, its Affiliates or Subcontractors and any such delays not under their control will be deemed to extend such period, commensurate with such delay.
  ? Successful completion of product scale-up and receipt of regulatory marketing approval by the end of year 3, provided there are no delays which are under the control of Licensee, its Affiliates or Subcontractors and any such delays not under their control will be deemed to extend such period, commensurate with such delay.
  ? First commercial sale by the end of year 3 in any of the following territories: US, Canada, Japan, western Europe, provided there are no delays which are under the control of Licensee, its Affiliates or Subcontractors and any such delays not under their control will be deemed to extend such period, commensurate with such delay.
  ? $50,000 in annual sales each year from years 5-9
  ? $100,000 in annual sales each year from year 10 onwards





August 20, 2018 - 10Q Edgar Search

August 14, 2018 - Edgar NT -10-Q



As a condition to the closing of the Exchange Transaction, effective July 31, 2018, the Board of Directors of the Company (the “Board”) appointed Aitan Zacharin as Director and Chief Executive Officer of the Company and Mark Radom as chief legal officer of the Company.

Mark Radom previously held the positions President, Chief Executive Officer, Chief Financial Officer, Treasurer and Secretary of Graphite Corp. Although there was no arrangement or understanding between Mark Radom and any other person(s) pursuant to which he was selected as chief legal officer of the Company, the Selling Shareholders decided on their own initiative to offer Mr. Radom the position of chief legal officer. Mark Radom has no family relationships with any director or executive officer of the Company, or persons nominated or chosen by the Company to become directors or executive officers. Furthermore, the Company is not aware of any transaction involving Mark Radom requiring disclosure under Item 404(a) of Regulation S-K, except for the Exchange Transaction.

The Board believes that Mr. Radom’s extensive experience in business development, management of complex projects and legal services in connection therewith will be invaluable in achieving the Company’s goals.

Professional History of Aitan Zacharin

Mr. Zacharin is an experienced executive with a broad knowledge in building and managing technology and consumer products businesses. In 2012, he co-founded Fuse Science, an innovative biotechnology company headquartered in Miami, Florida and Oxnard, California. Mr. Zacharin was responsible for the development and growth of the business from a seed stage R&D company to a publicly traded CPG and biotech business with multiple subsidiaries. During his tenure he was tasked with expanding the biotechnology IP portfolio, spearheading multiple in vitro studies, and growing the consumer products business. In scaling the company, Mr. Zacharin identified and hired executive talent to lead the commercialization strategy including the past President of SC Johnson Company and previous CEO of Champs and Footlocker Sports. He successfully led the company to raise over $10M in three over-subscribed rounds, as well as negotiated contracts with 26 world renowned athlete and celebrity brand ambassadors, which included top ranked pro golfer Tiger Woods. Under Mr. Zacharin’s leadership the company developed and commercialized multi-category consumer products through a retail footprint of 15,000 doors. Since his exit from Fuse Science, he has been advising and investing in mid to late stage technology startups, and assisting them with capitalization, business strategy and development, and accelerating growth. Mr. Zacharin holds dual degrees from the University of South Florida in Tampa Bay. He resides in Baltimore, Maryland, and maintains various board appointments both professionally and philanthropically.

Professional History of Mark Radom

From August 2015 to July 2018, Mr. Radom served as chief executive officer of Graphite Corp. From February 2010 through July 2015, Mr. Radom served as the chief carbon officer and general counsel of Blue Sphere Corporation. From 2009 through 2010, Mr. Radom was managing director of Carbon MPV Limited, a Cyprus company focused on developing renewable energy and carbon credit projects. From 2007 to 2009, Mr. Radom was general counsel and chief operating officer of Carbon Markets Global Limited, a London-based carbon credit and renewable energy project developer. Mr. Radom has extensive experience in business development in the renewable energy and carbon credit sectors. He has sourced over U.S. $100,000,000 in renewable energy, industrial gas and carbon credit projects and managed many complex aspects of their implementation. He was legal counsel for a number of carbon and ecological project developers and was responsible for structuring joint ventures and advising on developing projects through the CDM/JI registration cycle and emission reduction purchase agreements under the auspices of the Kyoto Protocol. Prior to this, he worked on Wall Street and in the City of London as a US securities and capital markets lawyer where he represented sovereigns, global investment banks and fortune 500 companies across a broad range of capital raising and corporate transactions. He is a graduate of Duke University and Brooklyn Law School. Mr. Radom is admitted to practice law in New York and New Jersey and speaks fluent Russ


(d)       Appointment of Directors

As a condition to the closing of the Exchange Transaction, effective July 31, 2018, the Board appointed Aitan Zacharin as a director of the Company. Mr. Zacharin does not have any family relationships with any other executive officers or directors of the Company, or persons nominated or chosen by the Company to become directors or executive officers. There is no arrangement or understanding pursuant to which Mr. Zacharin was appointed as a member of the Board. Furthermore, the Company is not aware of any transaction requiring disclosure under Item 404(a) of Regulation S-K, except for the Exchange Transaction. It is contemplated that Mr. Zacharin may serve on certain committees of the Board, but no such committee appointments have been made at this time.

Here's something more:


This document shows it dated at the bottom left.


July 10, 2018 - SEC Edgar Search GCAN EFFECTIVE


July 9, 2018 - GCAN ADDED and to be TRADING THIS WEEK


  Current Value
Daily List Date/Time 07/09/2018 12:02:54
Event Type Addition
Effective/Ex Date/Time 07/09/2018 00:00:00
Issue Type  
Symbol GCAN
Issue Name Greater Cannabis Co Inc Common Stock
ADR Ratio  
Maturity Date  
Market Category Other OTC
Offering Type No Restrictions
OATS Reportable (Rptbl) Flag Yes
Unit of Trade 100
Reg Fee Flag Yes
Daily List Comment  
Date/Time Event Type Eff/Ex Date/Time Symbol Issue Name Market
07/09/2018 12:02:54 Addition 07/09/2018 00:00:00 GCAN Greater Cannabis Co Inc Common Stock Other OTC
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GCAN News: Quarterly Report (10-q) 05/20/2019 03:11:11 PM
GCAN News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 05/15/2019 09:59:00 AM
GCAN News: Annual Report (10-k) 04/15/2019 06:25:45 AM
GCAN News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 03/28/2019 01:02:49 PM
GCAN News: Current Report Filing (8-k) 02/15/2019 12:31:21 PM
News News Alert: Quarterly Report (10-q) 05/20/2019 03:11:11 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#19685  Sticky Note Your new numbers from the T/A today for Sprycel 05/10/19 12:45:03 AM
#14470  Sticky Note Enough BS post: supyoscn 02/10/19 06:02:13 PM
#12962  Sticky Note Wow! I am really having a hard Fuzzy Bunny 01/13/19 09:07:28 PM
#5504  Sticky Note Yep! Credibility is Earned as Lessons are Learned! 29YEARINVESTOR 10/06/18 05:41:21 AM
#3648  Sticky Note GCAN which was once Greater Cannabis Co and Major Baker 09/24/18 02:32:41 PM
#20213   I agree 1 million with the exception of 29YEARINVESTOR 05/21/19 08:39:36 AM
#20212   Greater Cannabis Company, Inc. revealed 10-Q form on MR. GWINIS 05/21/19 08:33:49 AM
#20211   ROFLMAO, well I guess I will provide the answer: Sprycel 05/21/19 08:15:56 AM
#20210   Your a day late. It was out Sprycel 05/21/19 08:09:31 AM
#20209   Q-10 is out MR. GWINIS 05/21/19 08:05:08 AM
#20208   All I can say is the 10Q sure Sprycel 05/21/19 08:01:03 AM
#20207   I like the way Our latest LOI Sounds 29YEARINVESTOR 05/21/19 06:28:34 AM
#20205   GCAN- Good Times are definitely on the horizon.... DTakx007 05/21/19 12:48:07 AM
#20204   Yes...agreed...people need to READ. Fuzzy Bunny 05/20/19 11:31:59 PM
#20203   Well, those in doubt can't BS anymore. Sprycel 05/20/19 11:17:53 PM
#20201   I agree it's very quiet I'm board I'm Goldnuget 05/20/19 10:54:29 PM
#20200   The 10Q's facts proved all the BS False Sprycel 05/20/19 10:27:36 PM
#20197   Nobody cares. Stock is at .15. WillieWonka 05/20/19 07:04:01 PM
#20195   GCAN is about to ROCKET launch. Thinking about DTakx007 05/20/19 06:11:47 PM
#20194   The 10Q specifically states why the 9 million Sprycel 05/20/19 05:50:39 PM
#20193   That's a bummer I must if misunderstood what Goldnuget 05/20/19 05:50:28 PM
#20192   Yea, my Etrade acct wouldn’t let me x looking 4 a win 05/20/19 05:40:33 PM
#20191   Nobody asking why GCAN gave 9,000,000 price protected Fuzzy Bunny 05/20/19 05:37:56 PM
#20190   I smell a nice 20-40%+ increase tomorrow. LAInvestor32 05/20/19 05:26:28 PM
#20189   YEP! LOOKS FANTASTIC!! ALL THE BS Sprycel 05/20/19 05:15:35 PM
#20188   Is that the correct 10Q? Goldnuget 05/20/19 05:09:59 PM
#20187   10Q http://archive.fast-edgar.com/20190520/AW2YLG2CZ22R3ZQZ2A292ZX285PPZZ22Z2B2 Goldnuget 05/20/19 05:06:31 PM
#20186   True on the divies but the gcan stock Goldnuget 05/20/19 05:00:41 PM
#20185   Well I told everyone the 10Q would prove Sprycel 05/20/19 04:47:04 PM
#20184   WRONG! There is 2 types of short interest. 29YEARINVESTOR 05/20/19 04:45:49 PM
#20183   Can’t, I tried looking 4 a win 05/20/19 04:35:32 PM
#20182   Yup...nobody will know about it until after it Fuzzy Bunny 05/20/19 04:35:19 PM
#20181   Ending the short volume crap: Although some Fuzzy Bunny 05/20/19 04:22:45 PM
#20180   T/A is open to be contacted daily to Sprycel 05/20/19 04:18:12 PM
#20179   The TA's representations showing the float numbers are Fuzzy Bunny 05/20/19 04:14:12 PM
#20178   Guess that BS False and Misleading claim that Sprycel 05/20/19 04:11:03 PM
#20177   So does fidelity they don't like cannabis divies Goldnuget 05/20/19 04:05:26 PM
#20176   Typical scam. only "Income" is from toxic Fuzzy Bunny 05/20/19 04:03:41 PM
#20175   Probably.....Just like Wayne used them to skim the Fuzzy Bunny 05/20/19 03:56:31 PM
#20174   10Q Diogenes of Sinope 05/20/19 03:24:36 PM
#20173   Nice! Does that mean Aitian is setting GCAN 29YEARINVESTOR 05/20/19 03:05:35 PM
#20172   I think he is done already. Any No-Quarter 05/20/19 03:01:54 PM
#20171   I don't think you've been proven wrong yet. No-Quarter 05/20/19 02:59:58 PM
#20170   Yea! It looks like Wayne has shafted UNGS 29YEARINVESTOR 05/20/19 02:55:31 PM
#20169   Been saying that for weeks now and it Sprycel 05/20/19 02:51:47 PM
#20168   Screwing with the one who bought the 29,681 Sprycel 05/20/19 02:47:24 PM
#20167   You are probably correct, but this also means No-Quarter 05/20/19 02:46:57 PM
#20166   He created GCAN, ran up debts, sold the MR. GWINIS 05/20/19 02:34:09 PM
#20165   Below is what we know Wayne signed as No-Quarter 05/20/19 02:29:04 PM
#20164   Yup....Aitan setting up many companies to use to Fuzzy Bunny 05/20/19 02:25:11 PM
#20163   29681 bought at 1509 and immediately is put Sprycel 05/20/19 02:18:24 PM
#20161   Hay, it is 333 trade day today!!! Sprycel 05/20/19 01:57:41 PM
#20160   GCAN positioning itself to be the NEXT big DTakx007 05/20/19 01:21:13 PM
#20158   Etrade shareholder can shove the shares that has Sprycel 05/20/19 12:57:25 PM